1	Persistence of immunity against omicron BA.1 and BA.2 following
2	homologous and heterologous COVID-19 booster vaccines in
3	healthy adults after a two-doses AZD1222 vaccination
4	Suvichada Assawakosri ^{a,b} , Sitthichai Kanokudom ^{a,b} , Jira Chansaenroj ^a , Nungruthai
5	Suntronwong ^a , Chompoonut Auphimai ^a , Pornjarim Nilyanimit ^a , Preeyaporn Vichaiwattana ^a ,
6	Thanunrat Thongmee ^a , Thaneeya Duangchinda ^c , Warangkana Chantima ^{d,e} , Pattarakul
7	Pakchotanon ^c , Donchida Srimuan ^a , Thaksaporn Thatsanatorn ^a , Sirapa Klinfueng ^a , Natthinee
8	Sudhinaraset ^a , Nasamon Wanlapakorn ^a , Juthathip Mongkolsapaya ^{f,g} , Sittisak Honsawek ^{b*} , Yong
9	Poovorawan ^{a,h*}
10	^a Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
11	Bangkok, 10330, Thailand
12	^b Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,
13	Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,
14	Bangkok, 10330, Thailand
15	^c Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic
16	Engineering and Biotechnology (BIOTEC), National Science and Development Agency,
17	NSTDA, Pathum Thani 12120, Thailand
18	^d Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital,
19	Mahidol University, Bangkok 10700, Thailand
20	^e Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of
21	Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

- 22 ^fWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford,
- 23 Oxford, OX3 7BN, UK
- ^g Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford,
- 25 Oxford, UK.
- ^h FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand.
- 27 *Address correspondence to
- 28 Prof. Dr. Yong Poovorawan, Center of Excellence in Clinical Virology, Department of
- 29 Pediatrics, Faculty of Medicine, Chulalongkorn University. Bangkok, 10330 Thailand. E-mail:
- 30 yong.p@chula.ac.th
- 31 Prof. Dr. Sittisak Honsawek, Center of Excellence in Osteoarthritis and Musculoskeleton,
- 32 Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai
- 33 Red Cross Society, Bangkok, 10330, Thailand E-mail: Sittisak.h@chula.ac.th

3

34 Abstract

Objectives: The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to
 evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study
 aimed to provide evidence on a heterologous booster strategy to overcome the waning immunity
 against Omicron variants.

39 Methods: Participants who completed Oxford/AstraZeneca (hereafter AZD1222) for 5-7 months 40 were enrolled. The reactogenicity and persistence of immunogenicity in both humoral and 41 cellular response after a homologous or heterologous booster with the AZD1222 and mRNA 42 vaccines (BNT162B2, full or half-dose mRNA-1273) administered six months after primary 43 vaccination were determined.

44 **Results:** Total 229 individuals enrolled, a waning of immunity was observed 5-7 months after

45 the AZD1222-primed. Total RBD immunoglobulin (Ig) levels, anti-RBD IgG and focus

46 reduction neutralization test against Omicron BA.1 and BA.2 and T cell response peaked 14-28

47 days after booster vaccination. Both the full and half dose of mRNA-1273 induced the highest

48 response, followed by BNT162b2 and AZD1222. At 90 days, the persistence of immunogenicity

49 was observed among all mRNA-boosted individuals. Adverse events were acceptable and well

50 tolerated for all vaccines.

51 Conclusions: A heterologous mRNA booster provided a significantly superior boost of binding
52 and NAbs levels against the Omicron variant compared to a homologous booster in individuals
53 with AZD1222-primed vaccinations.

54 Keywords COVID-19; AZD1222; heterologous booster; omicron; neutralizing antibody; T
55 cells.

4

56 Introduction

57 Since the first emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 58 Omicron (BA.1/B.1.1.529) variant in November 2021, it has rapidly spread and became the 59 dominant variant circulating worldwide (WHO, 2022a, WHO HQ, 2022). The Omicron variant 60 harbors mutations within the Spike (S) protein, particularly 15 amino acid substitutions in the 61 receptor-binding domain (RBD) (Viana et al., 2022). Mutations within the RBD of the omicron 62 variant mediate antibody evasion and greatly increase transmissibility through enhanced affinity 63 for the angiotensin-converting enzyme 2 receptor (ACE2) (Mannar et al., 2022, McCallum et al., 64 2022, Tian et al., 2021). Recently, the Omicron variant was further classified into several 65 descendent sublineages, including BA.1, BA.1.1, BA.2, BA.2.2, and BA.3. (Viana et al., 2022). 66 As of March 2022, epidemiological data have suggested that BA.2 sublineages have been the 67 most common sublineage of Omicron worldwide, including the South-East Asia region (WHO, 68 2022b). Furthermore, like Thailand, epidemiological surveillance revealed that the proportion of 69 the BA.2 variant has increased and represented >90% of all positive cases reported since March 70 2022 (Puenpa et al., 2022). BA.1 and BA.2 share multiple mutations, but BA.2 also presents 71 unique viral characteristics of BA.1, such as higher reproduction rate, fusogenicity, and 72 pathogenicity (Viana et al., 2022, Yamasoba et al., 2022). Scientific knowledge on the difference 73 in ability between BA.1 and BA.2 to evade third dose vaccine-induced immunity is still limited. 74 Several coronavirus diseases 2019 (COVID-19) vaccines have been developed to combat the 75 COVID-19 infection. The AZD1222 vaccine has been the highly used vaccine accounting for 2.8 76 billion doses administered worldwide and 48.3 million doses in Thailand alone (AstraZeneca 77 PLC, 2022, MOPH, 2022). Although the vaccine effectiveness (VE) after two-dose AZD1222 78 was estimated at 64%–74.0% for preventing SARS-CoV-2 and other lineage infection (Clemens

5

79 et al., 2021, Falsey et al., 2021), waning of vaccine-induced immunity of both anti-IgG and the 80 NAbs from AZD1222-primed vaccinees has been documented. For example, the dramatically 81 decreased levels of NAbs after 5-6 months of two doses of AZD1222 vaccination showed an 82 inadequate response to control the spread of SARS-CoV-2, especially the Omicron variant 83 (Dejnirattisai et al., 2022, Planas et al., 2022, Shrotri et al., 2021). Like a previous study, NAbs 84 decreased substantially after six months of vaccination with BNT162b2 (Dejnirattisai et al., 85 2022). Furthermore, the increase in infection was related to the waning immunity as a function of 86 time after BNT162b2-primig (Goldberg et al., 2021, Levin et al., 2021). Thus, the decline in 87 vaccine-induced immunity markedly increased a few months after vaccination and may be the 88 potential cause of breakthrough infection. 89 There is a growing interest in using booster dose as a new strategy to combat waning immunity 90 after primary vaccination and the high transmissibility and immune evasion of the omicron 91 sublineages. To date, increasing evidence has supported that the booster dose of the mRNA 92 vaccine following BNT162b2-primed significantly increased protection against the Omicron 93 variant (Garcia-Beltran et al., 2022). Furthermore, a heterologous booster after six months of 94 two-dose CoronaVac demonstrated that a heterologous booster produced stronger immunity than 95 a homologous booster (Assawakosri et al., 2022). In individuals primed with AZD1222, a 96 heterologous boost with BNT162b2 exhibited more effectiveness in inducing NAbs against BA.1 97 than the homologous booster with AZD1222 (Dejnirattisai et al., 2022), but there were no data 98 against BA.2. These results implied that the heterologous booster strategy could provide stronger 99 immunity against Omicron infection. However, very limited knowledge is available on the 100 duration of immune protection after the third homologous or heterologous dose and when we 101 should consider an additional booster beyond the third dose.

6

102 Consequently, our objective was to study the persistence of immunogenicity beyond one month 103 following the third dose. In the same cohort, we also investigated NAb against the new emerging 104 omicron variant, particularly the BA.2 sublineage, the cellular response and the reactogenicity 105 after the homologous and heterologous booster dose administered at 6-month intervals in healthy 106 adults who were previously vaccinated with AZD1222.

107 MATERIALS AND METHODS

108 Study design

109 This prospective cohort study was conducted at the Clinical Trial Unit, the Center of Excellence

110 in Clinical Virology of Chulalongkorn University, Bangkok, Thailand, and was performed in

111 accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice

112 Guidelines (ICH-GCP). The participants were informed, and written consent was obtained before

113 enrollment.

114 Study participants

115 Between November 2021 and January 2022, a total of 229 subjects participated in this

116 prospective cohort study. The main inclusion criteria were: Thai adults over 18 years of age with

117 no previous or current diagnosis of COVID-19 infection and completed a two-dose vaccination

118 of the AZD1222 at an interval of 5-7 months during the enrollment period. The intervals between

119 two-dose AZD1222-primed were 8-10 weeks. In addition, participants with an autoimmune or

120 cancer disease, taking immunosuppressive drugs, or participants that were pregnant or

121 breastfeeding were excluded.

7

122 Study vaccine

- 123 All participants were divided into four groups by conveniently sampling 50-60 participants per
- 124 group based on vaccine availability and vaccinated with one of the following preparations;
- 125 including 1) viral vector: AZD1222 (AstraZeneca, Oxford, UK) (Folegatti et al., 2020), 2)
- 126 mRNA: BNT162b2 (Pfizer-BioNTech Inc., New York City, NY), 3) mRNA: 100 μg mRNA-
- 127 1273 (full-dose group) (Moderna Inc., Cambridge, MA), and 4) 50 µg mRNA-1273 (half-dose
- 128 group) (Jackson et al., 2020). The study flow is illustrated in Figure 1.

129 Reactogenicity Assessment

- 130 All participants were observed under the supervision of doctors after vaccination to prevent
- 131 anaphylaxis reactions. Participants received an online or paper-based self-monitoring record
- 132 survey seven days after vaccination. They observed the solicited local and systemic AEs,
- 133 including injection site pain, induration, redness, fever, headache, myalgia, arthralgia, nausea,
- 134 and vomiting.

135 Sample collection, total RBD Ig, and anti-RBD IgG/nucleocapsid assay

- 136 Blood samples from vaccinees were collected prior to vaccination and at every follow-up visit on
- 137 days 14, 28, and 90 after the booster dose. The samples of all participants were tested for
- 138 quantitative antibody levels of total RBD Ig using Elecsys SARS-CoV-2 S (Roche Diagnostics,
- 139 Basel, Switzerland), anti-RBD IgG, and anti-nucleocapsid IgG (anti-N IgG) using the SARS-
- 140 CoV-2 IgG assay (Abbott, Sligo, Ireland) (Kanokudom et al., 2022).

141 Surrogate virus neutralization assay for delta and omicron variants

- 142 A cPassTM SARS-CoV-2 surrogate virus neutralization test (GenScript Biotech, New Jersey) was
- 143 used to measure NAb titters against SARS-CoV-2 variants. Recombinant RBD from delta and
- 144 omicron strains and 96-well plates coated with recombinant human ACE2 was used

8

145 (Kanokudom et al., 2022). The percentage of inhibition of a sample was calculated, samples with
146 percent inhibition ≥ 30% were considered a "seropositive" for SARS-CoV-2 neutralizing
147 antibodies.

148 Focus reduction neutralization test (FRNT50)

149 The neutralization antibody titers against the variants BA.1 and BA.2 of SARS-CoV-2 Omicron

150 were measured. The Focus reduction neutralization assay was performed (Assawakosri et al.,

151 2022). The nucleotide sequences of the BA.1 and BA.2 variants are deposited in GenBank under

accession numbers: EPI_ISL_8547017 for BA.1 and EPI_ISL_11698090 for BA.2 variant. The

153 50% focus reduction percentage was calculated, and the inhibitory concentration (IC50) was

determined using PROBIT software. The detection limit of the assay is 1:20, and the NAbs

155 values below the limit were substituted with a titer of 10.

156 Interferon-gamma release assay.

157 The interferon-gamma (IFN-γ) release assay was performed to evaluate cell-mediated immunity

158 using QuantiFERON (QFN) SARS-CoV-2 RUO (Qiagen, Hilden, Germany) (Kanokudom et al.,

159 2022). Briefly, heparinized whole blood was added to a spike-peptides-coated tube (Ag1) to

160 stimulate CD4+ and (Ag2) to stimulate CD4+, and CD8+ T cells then incubated for 21 hours.

161 Plasma samples were then collected to measure IFN-γ levels by ELISA (Munro et al.). The IFN-

162 γ levels were expressed in IU IFN- γ /mL. Levels above 0.15 IU/mL were defined as seropositive.

163 Statistical analysis

164 G*power software version 3.1.9.6 was used to calculate the sample size. All statistical analyses

165 were conducted using the Statistical Package for the Social Sciences (SPSS) v.22 (SPSS Inc.,

166 Chicago, IL, USA). Figures were generated using GraphPad Prism v9.0 (GraphPad Software,

167	San Diego, CA, USA) and R v4.1.2. Software (R Foundation for Statistical Computing, Vienna,
168	Austria). Binding antibody and NAbs were logarithmically transformed, and comparison
169	between groups was performed using analysis of variance (Folegatti et al.) with Bonferroni
170	adjustment or Kruskal-Wallis H test for nonparametric data. The qualitative data comparison was
171	performed using Pearson's χ^2 or Fisher's exact test. The Wilcoxon signed rank test was used for
172	pairwise analysis. A <i>p</i> -value <0.05 was considered statistically significant.
173	RESULTS
174	Demographic data
175	From November 2021 to January 2022, 229 adults were enrolled in the study. All participants
176	were healthy Thai adults with a mean age of 50.05 (\pm 9.71) years, 55.72 (\pm 13.68) years, 50.66
177	(±12.95) years, and 57.02 (±12.28) years in group AZD1222, BNT162b2, full-dose mRNA-1273
178	and half-dose mRNA-1273, respectively. Most participants were female, 127 (55.5%)
179	participants, and the average interval between the second dose and the booster dose was 166.3
180	(128-229) days. Common comorbidities included dyslipidemia, hypertension, diabetes mellitus,
181	and allergy. Generally, the groups did not have significant differences in baseline characteristics,
182	including sex and common underlying diseases and the intervals between follow-up times.
183	However, the age of BNT162b2 and half-dose mRNA-1273 was significantly higher than that of
184	AZD1222 and mRNA-1273 arms. Participant characteristics are shown in Table 1. During the
185	study, 38 participants were lost to follow-up, five participants were excluded because they tested
186	positive for SARS-CoV-2 infection, and another five participants were excluded because they
187	had received a fourth vaccine dose.

10

188 Immunogenicity assessment

189 Total RBD Ig and anti-RBD IgG

- 190 There were no differences in total RBD Ig and anti-RBD IgG between four groups at baseline,
- 191 with geometric mean titer (GMT) 244 U/mL and 50.2 BAU/mL, respectively. Most participants
- 192 had a very low antibody titer at 5–7 months after completing the second AZD1222 vaccination.
- However, 14 days after boost, total RBD Ig levels were significantly elevated to 2069, 13651,
- 194 28172, and 25824 U/mL in the AZD1222, BNT162b2, mRNA-1273, and half-dose groups,
- 195 respectively (Figure 2A). Comparable trends with anti-RBD IgG levels were observed with
- 196 GMT 268, 2285, 3864, and 3976 BAU/mL (Figure 2B). It should be noted that the concentration
- 197 of total RBD Ig decreased to 1303, 3974, 5516, and 6120 U/mL 90 days after the third dose in
- 198 each group, respectively. The mRNA-1273 vaccine produced the highest immune response
- among all booster groups, followed by BNT162b2 and AZD1222, respectively. In comparison,
- 200 the GMT of total RBD Ig and IgG against RBD between full- and half-dose mRNA-1273 were
- 201 comparable at both 14 and 90 days (Supplementary Table 1). Anti-N IgG levels were also
- 202 measured. In this study, the anti-N IgG results showed that all participants were seronegative (cut
- 203 off 1.4) to anti-N IgG at each visit (Supplementary Figure 1).

204 Surrogate virus neutralization specific delta and Omicron variants

205 The sVNT against the Delta and Omicron variants was performed randomly in half of the

206 participants of each group. A subset of the sample was tested for Surrogate virus neutralization

- 207 (sVNT) in the pre-booster. At 28 days after boosters, the median percentage inhibition to the
- 208 Delta variant was significantly elevated to 93.5% in AZD1222, 96.9% in BNT162b2, 97.0% in
- 209 mRNA-1273 and 97.9% in half dose mRNA-1273 (Figure 3A). While a lower percentage of
- 210 inhibition was observed against Omicron variants with 15.0%, 67.1%, 64.6%, and 65.7% in

11

211	groups AZD1222, BNT162b2, mRNA-1273, and half-dose mRNA-1273, respectively (Figure
212	3B). These results suggested that heterologous boosted individuals achieved a higher level of
213	NAb against the Omicron variant than homologous boosted individuals. On day 90 after
214	vaccination, the median percentage of inhibition to the Delta variant decreased slightly to 78.0%
215	in the AZD1222-boosted group, while the other groups remained >97% inhibition. In contrast to
216	the Omicron variant, the median percentage inhibition was reduced to 9.0% for AZD1222,
217	33.2% for BNT162b2, 35.5% for mRNA-1273, and 38.7% for half-dose groups of mRNA-1273,
218	respectively. Correspondingly, the neutralizing activity against the Omicron variant was
219	significantly lower than that against the Delta variant (Figure 3C). The heterologous
220	AZD1222/mRNA prime-boosted achieved higher detectable neutralization activities against
221	omicron than the homologous boost at both the 28-day and 90-day timepoint (Supplementary
222	Table 2).

223 Focus reduction neutralization test

224 We determined the cross-neutralizing activity of NAbs against the BA.1 and BA.2 Omicron 225 variants after booster vaccination using the Focus reduction neutralization assay (FRNT50) in a 226 subset of samples. Most participants showed undetectable Nabs on day 0 with 75.0%, 100%, 227 45%, and 60% in each group. The GMT of NAbs against BA.1 was 32.2 (20.1-51.6), 166 (114-228 243), 548 (415-723), and 396 (275-571) 28 days after receiving AZD1222, BNT162b2, mRNA-229 1273, and half-dose mRNA-1273, respectively (Figure 4A). Similarly, GMTs of Nabs against 230 BA.2 were 45.6 (28.8-72.3), 248 (179-342), 324 (214-492), and 224 (156-322), respectively 231 (Figure 4B). Then, 90 days post-vaccination, the GMT levels decreased to 21.6 (13.5-34.8), 232 87.0 (54.5-139), 141(89.6-222), 119 (78.5-181) for BA.1 and 32.6 (22.0-48.3), 73.8 (56.1-233 97.2), 139 (85.6-226), 111 (75-163) for BA.2 in group, respectively. The NAb titers to BA.1

12

234	were comparable to BA.2 (Figure 4C-4D). Furthermore, higher activity was observed to
235	neutralize the omicron variant in the heterologous mRNA boosted than in homologous boosted
236	individuals.
237	Total interferon-gamma response
238	The IFN- γ release assay was used to measure the presence of T cell responses, for both CD4+
239	and CD8+ T cells. On day 0, the total IFN- γ level produced by CD4+/CD4+ and CD8+ was less
240	observed in 29/116 (25.0%) and 43/116 (37.1%) of all participants. Conversely, the
241	seropositivity rate for Ag1 CD4+ rapidly increased to 79.3% for BNT162b2, 89.3% for
242	mRNA-1273, 89.3% for the half-dose group on day 14, while the seropositivity rate for Ag2
243	CD4+ and CD8 + was 86.2%, 89.3% and 92.9%, respectively. Then it slightly decreased at 28
244	days after boosted (Figure 5A and 5B). The highest seropositivity rate in AZD1222-boosted
245	was 37.9% and 69.0%, indicating that AZD1222-boosted produced a lower T cell response
246	than the mRNA-boosted. Moreover, the persistence of T cell response was observed among
247	mRNA-boosted individuals on day 90 after vaccination, but not in AZD1222-boosted
248	individuals. Consequently, heterologous mRNA boost exhibited a stronger positive impact on T-
249	cell responses than the homologous booster in individuals previously vaccinated with AZD1222.
250	The levels of IFN-γ among all groups are summarized in Supplementary Table 3.

251 Reactogenicity assessment

Reactogenicities following the booster vaccination were as follows: the most common local vaccine reaction in the first seven days was injection site pain while the most common systemic reaction was myalgia (Figure 6A–6D). Comparison of AEs between groups revealed that the injection site pain, myalgia, and chilling were lower in individuals receiving AZD1222 than in other vaccines (Supplementary Figure 2A-C). However, most incidences of AE were reported as

13

mild-to-moderate in severity and resolved a few days after vaccination. Furthermore, the local
reactions AE was less frequent in half-dose mRNA-1273 than in full dose included injection site
pain (98.3% vs 86.0%), and swelling (20.8% vs. 30.0%). During the study period, no serious
adverse effects were observed among all groups. The summarize data of all AE were shown in
Supplementary Table 4.

262 **Discussion**

263 Herein, we report quantifications of total RBD Ig, anti-RBD IgG, Nab, and total IFN- γ levels 264 after homologous and heterologous booster in participants who received two doses of AZD1222 265 vaccine. We also show the reactogenicity profile of all vaccine boosters. We determined there was a significant increase in total Ig, anti-RBD IgG, neutralizing antibody, and cellular responses 266 267 14-28 days after the booster shot. The decay of the immune response was observed 90 days after 268 the initial boosted for all study arms. At 7 days after vaccination, all COVID-19 vaccines 269 administered as a booster dose had acceptable reactogenicity with mild to moderate AE and 270 generally resolved within a few days after vaccination. AE data indicated that homologous and 271 heterologous vaccine boosters presented a good safety profile in all healthy adults, consistent 272 with the previous study of third homologous and heterologous boosters in individuals primed 273 with the AZD-1222 or BNT162b2 vaccines (Flaxman et al., 2021, Munro et al., 2021). 274 Our findings revealed that following the first primary series of AZD1222, a waning immunity 275 was evidenced 5-7 months after vaccination. After the booster was implemented with both 276 homologous and heterologous vaccines, antibody binding levels increased significantly 277 compared to baseline. Half-dose mRNA-1273 elicited total Ig and IgG RBD responses equal to 278 the full-dose group, which is consistent with the previous observation of mRNA-1273 booster in 279 participants primed with two-doses of mRNA-1273 (Choi et al., 2021). Furthermore, individuals

14

280	boosted with full and half doses of mRNA-1273 possessed the highest levels of total RBD Ig and
281	anti-RBD IgG compared to those boosted with BNT162b2 and AZD1222. According to the
282	COV-BOOST study, the magnitude of anti-spike IgG in individuals receiving a heterologous
283	booster was significantly higher than the homologous booster (Munro et al., 2021). In addition,
284	similar results have been reported previously regarding the heterologous third dose in individuals
285	receiving triple inactivated or triple mRNA vaccine (Gagne et al., 2022, Liu et al., 2022, Wang et
286	al., 2022). Our results may suggest that a single shot heterologous booster could further enhance
287	the immune response by stimulating the memory B-cell response (Goel et al., 2021).
288	In accordance with those recent report from the UK, we found that NAbs after 5-7 months of
289	AZD1222-primed individuals rapidly waned to near or below the detection limit and were barely
290	neutralized against Delta and Omicron variants (Wu et al., 2022). Herein, we observed that the
291	heterologous mRNA-based booster, but not the AZD1222-boosted, effectively produced a high
292	level of cross-neutralization against SARS-CoV-2 variants 28 days after the booster dose. The
293	breadth and cross-reactivity of NAbs after the third dose may be related to increasing memory B
294	cell affinity maturation through extensive somatic hypermutation like those observed in a
295	previous mRNA-boosted study (Paschold et al., 2022). However, reductions in neutralizing
296	activity against Omicron variants were found compared with those against Delta variants, in both
297	BNT162b2-primed and CoronaVac-primed indivudals (Assawakosri et al., 2022, Pérez-Then et
298	al., 2022, Planas et al., 2022). Although the BA.2 sublineage was documented to have different
299	viral characteristics than BA.1. Our findings revealed that the neutralizing activity against the
300	BA.1 and BA.2 variants was comparable. These results are consistent with previous studies
301	indicating that BA.2 was only 1.4-fold lower in NAbs than the BA.1 variant after BNT62b2
302	booster in BNT162b2-primed and previously infected individuals (Chen et al., 2022, Yu et al.,

15

303 2022). Our finding indicated that mRNA vaccines encoding the ancestral strain-spike could
304 induce a potent cross-neutralizing antibody against Delta, Omicron, both BA.1 and BA.2
305 subvariants.

306 Since the NAbs are the leading correlation with protection against COVID-19 infection (Khoury 307 et al., 2021). In our cohort, individuals boosted with mRNA possessed high levels of NAbs titer 308 against BA.1 and BA.2 subvariants. The high NAb titers observed in this study were related to 309 the increase in VE protection against symptomatic disease caused by the Omicron and Delta 310 variants after mRNA booster vaccination among the AZD1222-primed individuals (Andrews et 311 al., 2022). Although >90% of all participants had detectable neutralizing antibody responses after 312 90 days of booster vaccination, the reduction in NAbs titers against the Omicron variant was 313 evident. Similarly, VE data substantially decreased from 70.1% to 60.9% in mRNA-1273-314 boosted and 62.4% to 39.6% in BNT162b2-boosted after 10 or more weeks of booster (Andrews 315 et al., 2022). Since there is an evident benefit of a fourth dose seven months after the third dose 316 (Munro et al., 2022), the result showed that the fourth booster elicited a high level of anti-spike 317 IgG in individuals receiving AZD1222/mRNA prime boosters. The additional fourth dose should 318 be optional for those who received the AZD1222 as the third dose due to the lower antibody 319 response in this group.

Besides humoral immune responses, vaccine-induced T cell responses have a potential role in cross-recognizing Alpha, Beta, Delta, and Omicron variants even if using a different vaccination regimen (Gao et al., 2022, Jarjour et al., 2021, Tarke et al., 2021). Because class I and II spike epitopes were 70-80% conserved, leading to the preservation of CD4+ and CD8+ T cell responses (Tarke et al., 2021). Thus, the CD4 + and CD8+ T cells responses have remained stable primarily in frequency and magnitude against all variants of concern. Our study showed

326	the CD4+ and CD8+ T cell-producing IFN- γ were rapidly restored after 14 days of the
327	heterologous booster vaccination. Additionally, >70% of the mRNA-boosted individuals
328	demonstrated seropositive for T cell-producing IFN- γ response after 90 days post-vaccination but
329	showed only 50% seropositive for T cell-producing IFN- γ response in AZD1222-boosted group.
330	Beyond humoral responses, the heterologous booster could enhance the adaptive T-cell response,
331	and the T-cell response may play an essential role as a second-level cross-protection against
332	other upcoming variants.
333	Potential limitations of our study include may be attributed to the loss of some participants
334	during follow-up. Moreover, the phenotype of CD4+ and CD 8+ T cells was not examined after
335	booster vaccination. Additional studies of 6-month and longer duration are needed to address the
336	long-term durability of the immune response to booster vaccination.
337	In conclusion, the heterologous mRNA vaccine has an acceptable safety profile and could
338	significantly enhance humoral and cellular responses after vaccination in AZD1222-primed
339	individuals. Additionally, the booster with full-dose and half-dose mRNA-1273 exhibited the
340	highest humoral and cellular immune responses at 90 days after the booster dose, followed by
341	BNT162b2 and AZD1222. Receiving a heterologous booster dose could provide immune
342	protection against new emerging SARS-CoV-2 variants.

17

343 Ethics approval and consent to participate

- 344 The study protocol was approved by the Institutional Review Board of the Faculty of Medicine
- of Chulalongkorn University (IRB numbers 690/64). The study was registered with the Thai
- Clinical Trials Registry (TCTR 20210910002).

347 Conflicts of Interest

348 The authors declare no conflict of interest.

349 Funding Statement

- 350 This work was supported by the Health Systems Research Institute (HSRI), National Research
- 351 Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn
- 352 University, and King Chulalongkorn Memorial Hospital and was partially supported by the
- 353 Second Century Fund (C2F), Chulalongkorn University. Thaneeya Duangchinda was supported
- 354 by National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No.

355 P2051613).

356 Acknowledgments

- 357 The authors are grateful for the Center of Excellence in Clinical Virology staff and all the
- 358 participants for helping and supporting this project. We also thank the Ministry of Public Health,
- 359 Chulabhorn Royal Academy, and Zullig pharma for providing the vaccines for this study.

18

360 **Reference list**

- Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine
 Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med.
 2022;386(16):1532-46.
- Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
 al. Neutralizing Activities against the Omicron Variant after a Heterologous Booster in
 Healthy Adults Receiving Two Doses of CoronaVac Vaccination. J. Infect. Dis. 2022.
 Doi: 10.1093/infdis/jiac092
- AstraZeneca PLC. First quarter 2022 results; 2022. Available from:
 https://www.astrazeneca.com/content/dam/az/PDF/2022/q1-2022/Q1-2022-results announcement.pdf.
- Chen L-L, Chu AW-H, Zhang RR-Q, Hung IF-N, To KK-W. Serum neutralisation of the SARS CoV-2 omicron sublineage BA.2. Lancet Microbe. 2022;3(6):e404.
- Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med.
 2021;27(11):2025-31.
- Clemens SAC, Folegatti PM, Emary KRW, Weckx LY, Ratcliff J, Bibi S, et al. Efficacy of
 ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in
 Brazil. Nat. Commun. 2021;12(1):5861.
- Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.
 1.1. 529 leads to widespread escape from neutralizing antibody responses. Cell.
 2022;185(3):467-84.e15.
- Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and
 Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med.
 2021;385(25):2348-60.
- Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and
 immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the
 UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet.
 2021;398(10304):981-90.
- Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary
 report of a phase 1/2, single-blind, randomised controlled trial. Lancet.
 2020;396(10249):467-78.
- Gagne M, Moliva JI, Foulds KE, Andrew SF, Flynn BJ, Werner AP, et al. mRNA-1273 or
 mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion,
 neutralizing antibodies and protection against Omicron. Cell. 2022;185(9):1556-71.e18.
- Gao Y, Cai C, Grifoni A, Müller T, Niessl J, Olofsson A, et al. Ancestral SARS-CoV-2-specific
 T cells cross-recognize the Omicron variant. Nat. Med. 2022;28(3):472-76.
- Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al.
 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS CoV-2 Omicron variant. Cell. 2022;185(3):457-66.e4.

Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6(58):eabi6950.

404	Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning
405	Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021;385(24):e85.
406	Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA
407	Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920-
408	31.
409	Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding COVID-19. Immunity
410	2021;54(1):14-8.
411	Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
412	al. Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector,
413	and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated
414	Vaccine. Vaccines 2022;10(1):86.
415	Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
416	antibody levels are highly predictive of immune protection from symptomatic SARS-
417	CoV-2 infection. Nat. Med. 2021;27(7):1205-11.
418	Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral
419	Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med.
420	2021;385(24):e84.
421	Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D, et al. Robust induction of B cell and T cell responses
422	by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022;8(1):10.
423	Mannar D, Saville JW, Zhu X, Srivastava SS, Berezuk AM, Tuttle KS, et al. SARS-CoV-2
424	Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2
425	complex. Science. 2022;375(6582):760-4.
426	McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al. Structural
427	basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science.
428	2022;375(6583):864-8.
429	Misnistry of Public Heath, Department of Disease Control; COVID-19 vaccine reported.
430	https://ddc.moph.go.th/dcd/pagecontent.php?page=641&dept=dcd (accessed 15 May
431	2022)
432	Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and
433	immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two
434	doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded,
435	multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258-76.
436	Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity,
437	and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-
438	dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose
439	of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised t. Lancet
440	Infect Dis. 2022;S1473-3099(22)00271-7.
441	Paschold L, Klee B, Gottschick C, Willscher E, Diexer S, Schultheiß C, et al. Rapid
442	hypermutation B cell trajectory recruits previously primed B cells upon third SARS-
443	CoV-2 mRNA vaccination. Front Immunol. 2022;13:876306.
444	Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al. Neutralizing
445	antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous
446	CoronaVac plus BNT162b2 booster vaccination. Nat. Med. 2022;28(3):481-5.
447	Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al.
448	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature
449	2022;602(7898):671-5.

450	Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, et al.
451	Molecular characterisation and tracking of the severe acute respiratory syndrome
452	coronavirus 2, Thailand, 2020–2022. Research Square Platform LLC; 2022.
453	Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al. Spike-antibody
454	waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385-7.
455	Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination
456	induces immunological memory able to cross-recognize variants from Alpha to Omicron.
457	bioRxiv 2021. Doi:10.1101/2021.12.28.474333
458	Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, et al. N501Y mutation of spike protein in
459	SARS-CoV-2 strengthens its binding to receptor ACE2. Elife. 2021;10:e69091.
460	Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic
461	expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature
462	2022;603(7902):679-86.
463	Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H, et al. Memory B cell repertoire from triple
464	vaccinees against diverse SARS-CoV-2 variants. Nature 2022;603(7903):919-25.
465	WHO. Statement on Omicron sublineage BA.2; 2022a. Available from:
466	https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-ba.2.
467	(Accessed March 23 2022).
468	WHO. COVID-19 Weekly Epidemiological Update Edition: World Health Organization (WHO).
469	2022b. [Available from: https://www.who.int/publications/m/item/weekly-
470	epidemiological-update-on-covid-195-april-2022. (Accessed April 8 2022)
471	WHO HQ. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions
472	for Member States. Available from: https://www.who.int/docs/default-
473	source/coronaviruse/20211217-global-technical-brief-and-priority-action-on-
474	omicron_latest-2.pdf?sfvrsn=bdd8297c_12. (Accessed March 23 2022).
475	Wu M, Wall EC, Carr EJ, Harvey R, Townsley H, Mears HV, et al. Three-dose vaccination
476	elicits neutralising antibodies against omicron. Lancet. 2022;399(10326):715-7.
477	Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological characteristics of
478	SARS-CoV-2 BA.2 variant. Cell. 2022;S0092-8674(22)00533-5.
479	Yu J, Collier A-RY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the SARS-
480	CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med. 2022;386(16):1579-80.

	Total	AZD1222	BNT162b2	mRNA-1273	Half mRNA-1273
Total number (n)	229	59	61	59	50
Age ± SD (year)					
Mean ± SD	53.24±12.55	50.05±9.71	55.72±13.68	50.66±12.95	57.02±12.28
Sex					
Male (%)	102 (44.5%)	23 (39.0%)	26 (42.6%)	30 (50.8%)	23 (46.0%)
Female (%)	127 (55.5%)	36 (61.0%)	35 (57.4%)	29 (49.2%)	27 (54.0%)
Underlying diseases (%)					
Allergy	14 (6.1%)	5 (8.5%)	5 (8.2%)	3 (5.1%)	1 (2.0%)
Cardiovascular diseases	s 4 (1.7%)	3 (5.1%)	1 (1.6%)	0 (0.0%)	0 (0.0%)
Diabetes Mellitus	19 (8.3%)	2 (3.4%)	8 (13.1%)	5 (8.5%)	4 (8.0%)
Dyslipidemia	46 (20.1%)	6 (10.2%)	17 (27.9%)	10 (16.9%)	13 (26.0%)
Hypertension	46 (20.1%)	9 (15.3%)	17 (27.9%)	7 (11.9%)	13 (26.0%)
Thyroid	4 (1.7%)	1 (1.7%)	3 (4.9%)	0 (0.0%)	0 (0.0%)
Others	20 (8.7%)	7 (11.9%)	10 (16.4%)	3 (5.1%)	0 (0.0%)
Follow-up Time					
Second visit					
Mean (range) day	14.7	14.6	16.0	14.1	14.0
	(12-20)	(14-20)	(14-19)	(13-15)	(12-21)
Third visit					
Mean (range) day	29.9	28.9	29.9	28.2	33.2
	(21-39)	(28-36)	(26-39)	(26-30)	(21-35)
Fourth visit					
Mean (range) day	94.5	90.3	102.8	91.8	94.4
	(89-114)	(90-92)	(93-114)	(89-100)	(90-104)

Table 1: Baseline characteristics of the participants enrolled in this study.

483 Figure







Figure 1. Diagram of the number of included participants and study groups. A total of 229
individuals who were previously vaccinated with AZD1222 were enrolled to analyze binding
antibodies and T cell responses in the cohort study. Blood samples were collected at 0, 14, 28,
and 90 days after booster vaccination. They were assigned to receive a booster vaccine including
AZD1222 (n=59) or BNT162b2 (n=61) or mRNA-1273 (n=59) or half-dose mRNA-1273
(n=50).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.05.22276016; this version posted June 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






491 Figure 2: Measurement of the SARS-CoV-2-specific binding antibody. (A) shows the total

492 RBD Ig (U/mL). (B) displays the anti-RBD IgG (BAU/mL). Each data point represents the level

- 493 of SARS-CoV-2-specific binding antibody in sera from an individual who completed two doses
- 494 of AZD1222, followed by the booster vaccine, including AZD1222 (purple), BNT162b2 (blue),
- 495 mRNA-1273 (green), or half-dose mRNA-1273 (yellow). The error bars indicate GMT and 95%
- 496 confidence intervals (95% CI). The dotted lines designate the cut-off values. ns indicates that
- 497 there is no statistical difference; **, p < 0.01, ***, p < 0.001.

24



498 Figure 3: Neutralizing activities of delta and omicron variants compared between pre-and

499 **post-boost using a surrogate virus neutralization test.** A subset of samples was randomly

500 selected to test for sVNT, including sera collected at baseline and sera collected 28 days after

- 501 boost (n=30/group). (A) Neutralizing activities against the SARS-CoV-2 Delta variant and (B)
- 502 Neutralizing activities against the SARS-CoV-2 Omicron variant (BA.1) were shown as
- 503 %inhibition. (C) Comparison of the neutralizing activity between the Delta and Omicron variants
- 504 after booster vaccination. Median values with interquartile ranges (IQRs) are denoted as
- 505 horizontal bars. Horizontal bars indicate the median. Dotted lines designate cutoff values (30%).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.05.22276016; this version posted June 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 4. Neutralizing antibody titers against Omicron BA.1 and BA.2 before and after booster vaccination. Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 was measured using the focus reduction neutralization test (FRNT50). (A) Neutralization against the BA.1 omicron variant and (B) Neutralization against the BA.2 omicron variant. (C) Comparison of NAb titers against BA.1 and BA.2 on 28 days after the booster dose. (D) Comparison of NAb titers against BA.1 and BA.2 on 90 days after the booster dose. Each data point represents an individual who received a booster vaccine, including the viral vector vaccine, AZD1222


26

513 (purple), the mRNA vaccine, BNT162b2 (blue), mRNA-1273 (green), or half-dose mRNA-

514 1273 (yellow). The error bars present GMT and the 95% confidence interval (CI). Values

515 below the limit were substituted with a titer of 10. ns indicates that there is no statistical

516 difference; **, *p*<0.01, ***, *p*<0.001.




517 Figure 5. Total CD4+ and CD8+ T cell-producing IFN-γ assay. The QFN IFN-γ ELISA

518 measured levels on days 0, 14, 28, and 90. (A) shows the IFN-γ produced by CD4+ (stimulated 519 with CD4+specific epitope RBD from RBD (Ag1)) and (B) shows the IFN-γ produced by CD4+ 520 and CD8+ T cell (stimulated with CD4+/CD8+ specific epitope derived from S1 and S2 subunits 521 (Ag2)). Each data point represents an individual who received a booster vaccine, including the 522 viral vector vaccine, AZD1222 (purple), the mRNA vaccine, BNT162b2 (blue), mRNA-1273 523 (green), or half-dose mRNA-1273 (yellow). Horizontal bars indicate the median. The dotted

524 lines designate the cut-off values.





526 Figure 6. Reactogenicity and severity of local and systemic reactions during the first seven 527 days following vaccination with a booster dose of COVID-19 vaccines. The booster vaccine 528 included the viral vector vaccine - AZD1222 (A), mRNA vaccine - BNT162b2 (B), mRNA 529 vaccine - mRNA-1273 (C), and the half dose mRNA-1273 (D). The percentage of participants 530 who reported adverse events is presented on the Y axis. Swelling and redness were classified by 531 measuring the diameter area as mild (<5 cm), moderate (5 to <10 cm), and severe (≥ 10 cm). 532 Fever was graded as mild ($38^{\circ}C$ to $<38.5^{\circ}C$), moderate ($38.5^{\circ}C$ to $<39^{\circ}C$), and severe ($>39^{\circ}C$). 533 The other events were classified as mild (no impact on regular activity)/ moderate (some 534 limitation of daily activity), and severe (unable to perform or prevented daily activity).